DELEX Therapeutics

As of September 30, 2009, DELEX Therapeutics Inc. was acquired by YM BioSciences Inc. DELEX Therapeutics Inc. is a biotechnology company that develops inhalation delivered fentanyl products to treat cancer pain. It offers ROSE-DS technology platform, a pulmonary delivery platform that provides rapid onset and sustained therapeutic effects. The company’s products include AeroLEF, which is used for the treatment of acute, chronic, and cancer pain; DLX0201, a product for nausea/vomiting in oncology patients; and DLX011, a product for neuropathic and chronic pain. The company was founded in 1999 and is based in Mississauga, Canada.